Humani Albumin Csl Behring (Human Plasma Protein)

Humani Albumin Csl Behring is indicated for several clinical conditions that involve reduced plasma volume or low albumin concentrations. It is employed when rapid restoration of oncotic pressure is needed.

• Management of hypovolemia due to trauma, surgery, or dehydration
• Treatment of shock associated with severe burns or sepsis
• Correction of hypoalbuminemia in liver disease or nephrotic syndrome
• Supportive therapy during large‑volume paracentesis or plasmapheresis
• Adjunct in cardiac surgery to maintain intravascular volume

• Humani Albumin Csl Behring supplies exogenous albumin, which increases plasma oncotic pressure by binding water and solutes within the vascular compartment. This osmotic effect draws fluid from the interstitial space back into the circulation, thereby expanding intravascular volume and improving tissue perfusion. The albumin molecule also serves as a carrier for endogenous substances such as hormones, fatty acids, and drugs, contributing to its physiological role in plasma homeostasis.

Adverse reactions to Humani Albumin Csl Behring are generally infrequent but can range from mild to severe.

Common

• Transient fever or chills during infusion
• Mild headache or dizziness
• Nausea or mild gastrointestinal discomfort
• Localized erythema or swelling at the injection site

Serious

• Anaphylactic or severe allergic reactions
• Acute hemolysis or renal impairment
• Volume overload leading to pulmonary edema
• Thromboembolic events in high‑risk patients

Humani Albumin Csl Behring should be administered with careful clinical assessment and monitoring.

• Assess fluid status and avoid use in patients with uncontrolled heart failure or severe pulmonary edema
• Monitor serum albumin and electrolytes before and after infusion
• Use caution in patients with known hypersensitivity to human albumin products
• Adjust infusion rate in individuals at risk for volume overload
• Consider renal function, especially in patients with pre‑existing kidney disease
• Avoid rapid bolus administration; follow recommended infusion guidelines

Humani Albumin Csl Behring may interact with other therapies that affect fluid balance or coagulation.

Avoid

• Concurrent use of high‑dose diuretics without close monitoring of volume status
• Simultaneous administration of other volume expanders that could precipitate overload

Use with caution

• Anticoagulants or antiplatelet agents, as albumin can alter plasma protein binding
• Vasopressors, because changes in intravascular volume may affect dosing
• Renal replacement therapies, which may modify albumin clearance
• Immunosuppressive drugs, due to potential changes in drug distribution